Chen Jing, Zhang Shenghua, Huang Xinmei, Wang Qianqian, Xu Weiyan, Huang Jing, Su Yuming, Sun Qinkun, Du Xiaojuan, Xing Baocai, Qiu Xiaoyan
Hepatopancreatobiliary Surgery Department I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, 100191, China; NHC Key Laboratory of Medical Immunology, Peking University, Beijing, 100191, China; Medicine Innovation Center for Fundamental Research on Major Immunology-related Diseases, Peking University, Beijing, 100191, China.
Neoplasia. 2025 Mar;61:101140. doi: 10.1016/j.neo.2025.101140. Epub 2025 Feb 25.
Liver metastasis is a leading cause of colorectal cancer mortality. Therefore, the underlying mechanism and potential therapeutic target of colorectal cancer liver metastasis urge to be found. Mounting evidence indicates that cancer-derived sialylated IgG promotes tumor formation and progression. However, the role of sialylated IgG in colorectal cancer liver metastasis remains undefined.
Analysis of sialylated IgG in paired tumor tissues and adjacent normal tissues from 65 colorectal cancer patients was performed using immunohistochemical staining. Functional assays of sialylated IgG were explored in vitro and in vivo. The downstream target of sialylated IgG was investigated by performing gene-set enrichment analysis, ubiquitination assay, cycloheximide chase assay, acetylation assay and co-immunoprecipitation.
Here, our investigation reveals that sialylated IgG is significantly upregulated in colorectal cancer and that the increase of IgG is positively associated with liver metastasis and poor overall survival in colorectal cancer patients. Sialylated IgG promotes colorectal cancer cell migration, invasion and liver metastasis. Notably, anti-sialylated IgG antibody effectively blocks colorectal cancer liver metastasis in mouse models. Mechanistically, sialylated IgG upregulates c-Myc protein level by decreasing c-Myc ubiquitination. Moreover, we find that p300/CBP can stabilize c-Myc by reducing c-Myc ubiquitination. Overexpression of p300/CBP protects c-Myc protein level from sialylated IgG-knockdown in a lysine acetyltransferase activity-dependent manner. Furthermore, sialylated IgG upregulates p300 protein level through integrin β4-FAK-Src-Erk signaling.
Collectively, these results indicate that a novel sialylated IgG-integrin β4-FAK-Src-Erk-p300-c-Myc signaling pathway promotes colorectal cancer liver metastasis, thus providing potential therapeutic targets for colorectal cancer liver metastasis.
肝转移是结直肠癌死亡的主要原因。因此,迫切需要找到结直肠癌肝转移的潜在机制和治疗靶点。越来越多的证据表明,肿瘤来源的唾液酸化IgG促进肿瘤的形成和进展。然而,唾液酸化IgG在结直肠癌肝转移中的作用仍不明确。
采用免疫组织化学染色法分析65例结直肠癌患者配对肿瘤组织和癌旁正常组织中唾液酸化IgG的表达。在体外和体内研究唾液酸化IgG的功能。通过基因集富集分析、泛素化检测、放线菌酮追踪检测、乙酰化检测和免疫共沉淀等方法研究唾液酸化IgG的下游靶点。
本研究发现,唾液酸化IgG在结直肠癌中显著上调,IgG的增加与结直肠癌患者的肝转移和总体生存率差呈正相关。唾液酸化IgG促进结直肠癌细胞的迁移、侵袭和肝转移。值得注意的是,抗唾液酸化IgG抗体可有效阻断小鼠模型中的结直肠癌肝转移。机制上,唾液酸化IgG通过减少c-Myc泛素化上调c-Myc蛋白水平。此外,我们发现p300/CBP可通过减少c-Myc泛素化来稳定c-Myc。p300/CBP的过表达以赖氨酸乙酰转移酶活性依赖的方式保护c-Myc蛋白水平免受唾液酸化IgG敲低的影响。此外,唾液酸化IgG通过整合素β4-FAK-Src-Erk信号通路上调p300蛋白水平。
这些结果共同表明,一条新的唾液酸化IgG-整合素β4-FAK-Src-Erk-p300-c-Myc信号通路促进结直肠癌肝转移,从而为结直肠癌肝转移提供了潜在的治疗靶点。